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OBJECTIVES We sought to assess the relationship of antecedent hypertension to neurohormones,
ventricular remodeling and clinical heart failure (HF) after myocardial infarction (MI).
BACKGROUND Heart failure is a probable contributor to the increased mortality observed after MI in those
with antecedent hypertension. Hence, neurohormonal activation, adverse ventricular remod-
eling and a higher incidence of clinical HF may be expected in this group. However, no
previous report has documented serial postinfarction neurohumoral status, serial left ventric-
ular imaging and clinical outcomes over prolonged follow-up in a broad spectrum of patients
with and without antecedent hypertension.
METHODS Inpatient events were documented in 1,093 consecutive patients (436 hypertensive and 657
normotensive) with acute MI. In 68% (282 hypertensive, 465 normotensive) serial neuro-
hormonal sampling and radionuclide ventriculography were performed one to four days and
three to five months after infarction. Clinical outcomes were recorded over a mean follow-up
of two years.
RESULTS Plasma neurohormones were significantly higher in hypertensives than in normotensives one
to four days and three to five months after infarction. From similar initial values, left
ventricular volumes increased significantly in hypertensives, compared with normotensives.
Left ventricular ejection fraction rose significantly in normotensive but not hypertensive
patients. Together with higher inpatient (8.1% vs. 4.4%, p  0.002) and post-discharge
mortality (9.5% vs. 5.5%, p 0.043), hypertensive patients incurred more inpatient HF (33%
vs. 24%, p 0.001) and more late HF requiring readmission to hospital (12.4% vs. 5.5%, p
0.001). Antecedent hypertension predicted late HF in patients 64 years of age with
neurohormonal activation and early left ventricular dilation.
CONCLUSIONS Antecedent hypertension interacts with age, neurohumoral activation and early ventricular
remodeling to confer greater risk of HF after MI. (J Am Coll Cardiol 2002;39:1182–8)
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Although antecedent hypertension is known to adversely
affect mortality after acute myocardial infarction (MI) (1–9),
whether (and in which patients) it also heightens the risk of
developing heart failure (HF) is disputed (3,6,10–12).
Furthermore, the potential interactions of antecedent hy-
pertension with other predictors of postinfarction HF (in-
cluding neurohormonal activation and left ventricular di-
mensions) are not well defined. Because hypertension
induces structural changes within the left ventricle (13–17),
we hypothesized that patients with hypertension would
more often develop clinical HF and would exhibit greater
activation of neurohormonal systems and more frequent
adverse ventricular remodeling after acute MI than would
normotensive individuals. The current report is the first to
document serial postinfarction neurohormonal status and
serial left ventricular imaging (radionuclide scanning) to-
gether with prolonged follow-up of clinical outcomes in a
substantial series of patients with and without antecedent
hypertension.
METHODS
The study population was 1,093 patients admitted to the
Christchurch Hospital Coronary Care Unit (CCU) with
acute MI between November 1994 and June 1999. Acute
MI was defined by the combination of typical symptoms
together with ischemic changes in two or more ECG leads,
and elevation of plasma creatine kinase (CK) to at least
twice the upper limit of normal (400 U/l). Criteria for
inclusion were age 80 years, absence of cardiogenic shock
and survival for at least 24 h after onset of symptoms.
Patients were categorized as having antecedent hypertension
if this diagnosis was known by the patient to have been
made by their family physician or after specialist referral, if
the acute admission note indicated a history of hypertension
and/or they were receiving antihypertensive medication.
Seven hundred and forty seven patients (68% of the
group) gave written informed consent for additional tests
and follow-up, according to a protocol approved by the
Ethics Committee (Canterbury) of the Health Funding
Authority of New Zealand. Blood samples for measurement
of plasma atrial natriuretic peptide (ANP), brain natriuretic
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peptide (BNP), the amino terminal congeners of both ANP
and BNP (N-ANP and N-BNP), cyclic guanosine mono-
phosphate (cGMP), plasma catecholamines, adrenomedul-
lin (ADM) and plasma endothelin-1 (ET-1) (18–24) were
collected 24–96 h after the onset of symptoms through an
indwelling intravenous cannula placed at least 30 min before
sampling, with the patient resting quietly, semirecumbent.
Samples were taken into chilled EDTA vacutainers, centri-
fuged within 20 min at 4°C and the plasma stored at80°C
before assay. Radionuclide ventriculography was performed
within 24 h of blood sampling, with a General Electric 400
(Philadelphia, Pennsylvania) AC gamma camera interfaced
to a General Electric 3000I computer system after standard
in vivo technetium 99M red blood cell labeling. In survivors,
both neurohumoral blood sampling and radionuclide scan-
ning were repeated three to five months after MI.
Clinical events, including death, predischarge HF (pres-
ence of new symptoms of dyspnea and/or edema, with one
or more of ventricular gallop rhythm, pulmonary crepita-
tions, elevated venous pressure and/or radiologic evidence of
left ventricular failure) and later readmissions for HF
(similarly defined), were recorded for a mean follow-up
period of two years. Patients were reviewed at 4 and 12
months after MI, then received questionnaires on clinical
progress (with telephone follow-up) annually. Deaths were
confirmed by death certificate and by consultation with
medical staff responsible for inpatient care or with the family
physician.
Statistical analysis. Values are expressed as mean  stan-
dard deviation or standard error of the mean. Categorical
clinical and demographic features and mean values of
plasma hormones and nuclear ventriculography scan data
were compared between normotensive and hypertensive
groups by chi-square or independent t tests. Adverse event
rates were compared (log rank test) by Kaplan-Meier
survival analysis. Cox proportional hazards or multiple
regression analyses were conducted to test the independent
predictive power of antecedent hypertension and other
putative indicators for predefined end points, including
inpatient left ventricular failure and postdischarge cardiac
failure requiring readmission to hospital. A p value 0.05
(two-tailed) was considered statistically significant.
RESULTS
Patient characteristics. Of 1,093 patients, 436 (40%) had
antecedent hypertension. Hypertensive patients were, over-
all, slightly older; a greater proportion were female, had a
higher body mass index, were more likely to have diabetes
and/or renal dysfunction (plasma creatinine 0.11 mmol/l)
and had more previously recognized dyslipidemia, compared
with normotensive patients (Table 1). On the other hand,
smoking was less prevalent in hypertensives than in normo-
tensives. Rates of previous MI and HF were similar.
Peak CK levels (2,066  1,724 vs. 2,199  1,983 U/l;
p  0.265) and the proportion of patients suffering anterior
MIs (42% and 39%; p  0.336) were similar in hyperten-
sives and normotensives, respectively. There was a trend
towards more frequent primary ventricular fibrillation in
hypertensives (8.2% vs. 5.8%; p 0.151 NS). Thrombolytic
therapy was administered in a slightly greater proportion of
normotensives (61%) than of hypertensive patients (54%;
p 0.020), although in the subgroup (n 747) undergoing
more detailed testing and follow-up, this difference was not
significant.
At discharge, rates of angiotensin-converting enzyme
(ACE) inhibitor (53% vs. 36%, p  0.001) and diuretic
(27% vs. 16%, p  0.001) use were significantly greater in
hypertensive patients than in normotensive patients,
whereas prescription of beta-blockers, antilipid agents and
aspirin did not differ.
Neurohormones. Plasma norepinephrine, the cardiac na-
triuretic peptides, their N-terminal propeptides and plasma
cGMP levels were significantly higher in the hypertensive
group one to four days after MI and/or three to five months
after MI (Table 2), with these differences becoming statis-
tically more robust with the passage of time. In contrast,
plasma epinephrine, ADM and ET-1 levels did not differ
between groups at either time point.
Radionuclide ventriculography. Radionuclide ventricu-
lography indicated similar or smaller left ventricular systolic
(85  2.5 vs. 89  2.3 ml; p  0.28) and diastolic (152 
2.9 vs. 160 2.6 ml; p 0.041) volumes and mean ejection
fractions (46.8  0.8 vs. 46.4  0.6%; p  0.656 NS) in
Abbreviations and Acronyms
ACE  angiotensin-converting enzyme
ADM  adrenomedullin
ANP  atrial natriuretic peptide
BNP  brain natriuretic peptide
cGMP  cyclic guanosine monophosphate
CK  creatine kinase
ECG  electrocardiogram
ET-1  endothelin 1
HF  heart failure
MI  myocardial infarction
N-ANP  aminoterminal atrial natriuretic peptide
N-BNP  aminoterminal brain natriuretic peptide
Table 1. Myocardial Infarction Patients With and Without
Antecedent Hypertension (n  1,093)
Normotensive
(n  657)
Hypertensive
(n  436) p Values
Age (yrs) 63.1  11.2 64.5  10.1 0.039
Female (%) 23 34 0.001
Weight (kg) 76.9  14.6 78.1  14.2 0.204
BMI (kg/m2) 26.3  4.1 27.5  4.6 0.001
Smoking (%) 31 23 0.003
Diabetes (%) 10 16 0.002
Renal dysfunction 4.1 10.2 0.001
Dyslipidemia (%) 25 36 0.001
Previous MI (%) 17 21 0.127
Previous HF (%) 8 8 0.925
Italic p values are statistically significant.
BMI  body mass index; HF  heart failure; MI  myocardial infarction.
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hypertensives compared to normotensives, one to four days
after MI. Left ventricular volumes increased in hypertensive
patients, compared with normotensive patients, over the
three- to five-month follow-up period (p  0.05 to p 
0.001). Ejection fraction rose in normotensive but not
hypertensive patients (p  0.01; Fig. 1).
Multiple regression analysis for independent prediction of
increases in left ventricular systolic volume after MI indi-
cated the following. Of 13 demographic, clinical, pharma-
ceutical and neurohormonal indicators (including age, gen-
der, peak CK, previous MI, previous HF, diabetes, renal
impairment, dyslipidemia, ACE inhibitor use at discharge,
beta-blocker use at discharge, diuretic use at discharge,
plasma BNP and hypertension), antecedent hypertension
was the single most powerful independent predictor (p 
0.001), with age (p  0.003) and plasma BNP (p  0.03)
also remaining significant. When all other neurohormonal
variables were rotated through this model in place of BNP,
none attained statistical significance.
Mortality and HF. Hypertensive patients, compared with
normotensive patients, had a higher inpatient mortality
(8.1% vs. 4.4%; p  0.002) and postdischarge mortality
(9.5% vs. 5.5%; p  0.043; Fig. 2). Hypertensives also had
a greater chance of developing acute left ventricular failure
(33% vs. 24%; p 0.001) or later HF requiring readmission
to hospital (12.4% vs. 5.5%; p 0.001; Fig. 2). Multivariate
testing indicated antecedent hypertension, age, previous
MI, diabetes, renal impairment and peak CK levels were all
independently predictive of inpatient LVF (p 0.05 to p
0.001).
Multivariate analysis incorporating seven putative predic-
tors (age, gender, peak CK, left ventricular ejection fraction,
history of diabetes, previous MI and hypertension) indicated
antecedent hypertension, age, left ventricular ejection frac-
tion and previous MI were all significant independent
predictors of postdischarge cardiac failure (p  0.002 for
all). These variables remained significant when neurohu-
moral factors were separately rotated through this multivar-
iate model (as an eighth variable) and early plasma concen-
trations of BNP (p  0.001), N-BNP (p  0.01), ANP
(p  0.001), N-ANP (p  0.05) and endothelin (p  0.05)
were all also significantly and independently predictive of
late HF.
Significant interactions were seen between a diagnosis of
antecedent hypertension and the following variables (for
Table 2. Plasma Hormones (Mean  SD) After MI in Patients
With and Without Antecedent Hypertension
Hormone Normotensive Hypertensive p Values
ANP (pmol/l)
A 31  19 40  33 0.006
B 28  17 37  27 0.001
N-ANP (pmol/l)
A 1,723  1,528 1,903  1,456 0.382
B 1,765  1,243 2,200  1,634 0.010
BNP (pmol/l)
A 26  15 30  19 0.046
B 17  12 21  19 0.012
N-BNP (pmol/l)
A 160  150 192  175 0.034
B 76  80 111  134 0.001
cGMP (nmol/l)
A 6.95  3.4 7.20  3.5 0.770
B 6.70  3.2 8.00  3.8 0.001
Noradrenaline (pmol/l)
A 2,588  1,492 2,846  1,475 0.048
B 2,185  984 2,526  1,156 0.001
Adrenaline (pmol/l)
A 211  152 235  191 0.162
B 176  126 186  124 0.766
ADM (pmol/l)
A 14  9 14  8 1.00
B 10  10 9  4 0.444
ET1 (pmol/l)
A 2.69  1.3 2.54  1.1 0.550
B 2.28  0.8 2.39  0.8 0.532
p values are corrected for multiple comparison using the Bonferroni correction. Italic
p values are statistically significant.
A  plasma hormone concentration one to four days after infarction; ADM 
adrenomedullin; ANP  atrial natriuretic peptide; B  plasma hormone concentra-
tion three to five months after infarction; BNP  brain natriuretic peptide; cGMP 
cyclic guanosine monophosphate; ET1  endothelin 1; N-ANP  amino-terminal
atrial natriuretic peptide; N-BNP  amino-terminal B-type natriuretic peptide.
Figure 1. Change (; mean  SEM) in left ventricular systolic volume
(LVESV; top panel), left ventricular diastolic volume (LVEDV; middle
panel) and left ventricular ejection fraction (LVEF; bottom panel)
between measurements at 24 to 96 h after infarction and a mean of four
(three to five) months after infarction in normotensive (solid columns) and
hypertensive (cross-hatched columns) patients. *p  0.05, **p  0.01,
†p  0.001.
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which interaction terms were separately rotated through the
multivariate model in place of the simple “hypertension”
term): age; peak CK; left ventricular end systolic volume;
left ventricular end diastolic volume; and initial plasma
levels of BNP, N-BNP, N-ANP, endothelin, ADM (ANP,
cGMP, norepinephrine and epinephrine), for the indepen-
dent prediction of post-discharge HF. The concurrence of
antecedent hypertension with above-median levels of age,
peak CK, any of the above listed neurohormones or of left
ventricular volumes was independently associated with sig-
nificantly (p  0.01 for all interactions) increased risk of
HF. Particularly, striking interactions modifying the rela-
tionship of antecedent hypertension to risk of postdischarge
HF were observed for age, plasma N-BNP and left ventric-
ular end systolic volume (all p  0.0001) as illustrated in
detail in Figure 3.
Cumulative admissions for HF in younger (below me-
dian, i.e., 64 years of age) hypertensive patients (4.5%)
exceeded those in younger normotensive patients (3.3%) by
only 1.2% (p NS). Corresponding event rates were 19.7%
and 7.9%, respectively, in older patients (i.e., an absolute
difference of 11.8%, p  0.001; 9.8 times the difference
observed in younger patients). Corresponding event rates
and the intergroup differences for patients with N-BNP
below versus above the group median (120 pmol/l) were
4.0% versus 2.0% (difference 2.0%, p  NS) and 20.5%
versus 11.1% (difference 9.4%, p  0.001; 4.7 times the
difference observed in the absence of elevated N-BNP).
Figure 2. Event-free survival curves for postdischarge all-cause mortality (Death; upper panel) and postdischarge heart failure requiring readmission to
hospital (Heart Failure; lower panel) in normotensive (NT; single line) and hypertensive (HT; double line) patients after acute myocardial infarction.
*p  0.05, †p  0.001.
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Finally, for left ventricular end-systolic volume below versus
above the median (78 ml), corresponding event rates and
intergroup differences were, respectively, 5.8% versus 1.9%
(difference 3.9%, p  NS) and 20.3% versus 8.1% (differ-
ence 12.2%, p  0.001; 3.1-fold the difference in the
subgroups with smaller systolic volumes).
DISCUSSION
Hypertension is a well-established risk factor for coronary
artery disease and acute MI (25,26). Effects of chronic
hypertension, which may predispose patients to an adverse
effect on outcomes after acute MI, include increased coro-
Figure 3. Event-free survival curves for postdischarge heart failure requiring readmission to hospital in normotensives (dotted and dashed lines; groups
NT1 and NT2) and hypertensives (solid lines; groups HT1 and HT2) according to age (top panel), aminoterminal brain natriuretic peptide (N-BNP) (middle
panel) and left ventricular systolic volume (LVESV) (lower panel) equal or below (dotted [NT1] and light solid [HT1] lines) and above (dashed [NT2] and
heavy solid [HT2] lines) overall median values. Medians: age  64.1 years; N-BNP 120 pmol/l; LVESV 78 ml. *p  0.05, **p  0.01, †p  0.001.
1186 Richards et al. JACC Vol. 39, No. 7, 2002
HF After MI With Antecedent Hypertension April 3, 2002:1182–8
nary vascular resistance, decreased coronary reserve, pre-
existing muscle fiber hyperplasia and augmented interstitial
collagen together with possible alterations in the respon-
siveness of the coronary vasculature to vasoactive transmit-
ters (13–17). The weight of evidence indicates an adverse
effect of antecedent hypertension on survival after MI (1–9).
Hypertension is also a common substrate for HF (27–29),
which has a high mortality (28). In those with antecedent
hypertension, increased propensity to HF after MI may
contribute to this group’s increased postinfarction mortality.
However, reports of the relative frequency of acute and/or
chronic postinfarction HF in hypertensive compared with
normotensive patients, are scant and conflicting (3,6,10–12).
We assessed the importance of antecedent hypertension
in a large cohort recruited from a single center over a
five-year period. Consecutive patients (except for study
exclusions and declined consent) were studied. Follow-up
averaged two years. To our knowledge, this is the first report
from a substantial consecutive series of patients with MI
(including a broad spectrum of severity) that compares
outcomes in normotensive and hypertensive patients and
incorporates serial left ventricular imaging and serial neu-
rohormonal profiling, in addition to documenting clinical
outcomes.
Neurohormones. We found that patients with hyperten-
sion exhibited greater activation of neurohormones, both in
the early postinfarction period and several months later.
Such neurohumoral activation has been shown to have
prognostic significance after MI (30–32). This distinction
between groups was observed for the cardiac natriuretic
peptides and plasma norepinephrine. This implies greater
cardiac hemodynamic stress for a given infarct size in
hypertensive patients. Plasma levels of the cardiac peptides
reflect intracardiac pressures (33,34). Ventricular filling
pressures were, therefore, presumably greater in the hyper-
tensive group. Diastolic function also influences plasma
cardiac peptide levels (35) and is likely to have been more
impaired in hypertensive ventricles secondary to hypertro-
phic and interstitial changes attendant upon chronic hyper-
tension.
Ventriculography. In association with neurohumoral acti-
vation, significant left ventricular dilation occurred in the
hypertensive group, with mean increases in systolic and
diastolic volume clearly greater in hypertensive than in
normotensive subjects. Both antecedent hypertension and
plasma BNP were significant independent predictors of
increasing left ventricular systolic volume.
Mortality and HF. Most importantly, our data indicate
that patients with antecedent hypertension suffer increased
acute and chronic mortality and cardiac failure after MI.
This finding is consistent with evidence indicating that 90%
of patients who eventually present with overt cardiac failure
have an antecedent history of hypertension (27). The
association of antecedent hypertension with adverse out-
comes is amplified by age 64 years, more marked neuro-
humoral activation (N-BNP 120 pmol/l) and more pro-
nounced left ventricular dilation (LVESV 78 ml). In fact,
in the absence of these features, hypertension carried no
overall adverse prognostic significance (Fig. 3).
Differences between normotensive and hypertensive
groups in age, gender, body mass index, smoking and
diabetes confirmed multiple previous reports (3,5,6). How-
ever, when adjustment (multivariate analysis) was made for
these baseline differences, antecedent hypertension contin-
ued to independently predispose patients to HF. Notably,
peak CK levels, the frequency of anterior MI and the early
postinfarct left ventricular ejection fraction and dimensions
did not indicate greater initial infarct size in the hyperten-
sive group. Furthermore, greater neurohormonal activity,
mortality and morbidity occurred in those with antecedent
hypertension, despite significantly greater prescription of
ACE inhibitors and diuretics than in normotensive subjects
(53% vs. 36% and 27% vs. 16%, respectively; p  0.001 for
both comparisons). Therefore, the hypertensive heart is
more vulnerable to adverse left ventricular remodeling and
progression to frank congestive cardiac failure for a given
infarct size. This may reflect the mechanisms as discussed
previously (13–17).
Study limitations. Limitations of this report include in-
ability to comment on outcomes in the age80 years group
or on any non-Caucasian patient populations. Also, we did
not have detailed serial pre-infarction blood pressure re-
cordings. Furthermore, the effects of MI, bed rest and
postinfarct drug therapy probably obscured new diagnosis of
hitherto unrecognized hypertension. These factors and pro-
spective epidemiologic evidence (1) suggest that underesti-
mation of the true prevalence of antecedent hypertension in
our study population is likely. However, our observed
prevalence of 40% matches other recent reports (3,4,9) and
our data indicate that antecedent hypertension as defined in
the current report is of clinical importance.
Conclusions. In summary, antecedent hypertension inter-
acts with patient age, neurohormonal status and adverse
ventricular remodeling to confer increased risk of progres-
sion to congestive cardiac failure after MI.
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